Table 1.
Characteristics of Patients With Advanced NSCLC With BRCA Alterations at the Time of Enrollment in SAFIR02-Lung Trial
| Patient | Sex M/F | Age | Smoking (packs/y) | Histology | Cancer Family History | BRCA origin | Mutation | Status | Metastatic Sites | Best RRa |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 67 | CS (40) | ADC | N | S | BRCA1 | D | Bone, lymph nodes | PD |
| 2 | M | 60 | CS (40) | ADC | UK | S | BRCA1 | D | Muscle, lung | SD |
| 3 | M | 65 | CS (47) | ADC | N | S | BRCA2 | D | Suprarenal, bone, CNS, liver, lymph nodes | SD |
| 4 | M | 48 | CS (30) | ADC | UK | S | BRCA2 | D | Suprarenal, bone, liver, lymph nodes | SD |
| 5 | M | 62 | CS (88) | SCC | UK | S | BRCA2 | D | Bone, carcinomatous lymphangitis, lung, lymph nodes, muscle, pleura | PR |
| 6 | M | 65 | CS (45) | ADC | Y Colon Breast |
S | BRCA2 | D | Bone, lung, lymph nodes, pleural | SD |
| 7 | M | 60 | CS (30) | ADC | UK | G | BRCA2 | D | Bone, liver, lung, lymph nodes | SD |
| 8 | M | 68 | NS | ADC | Y Pancreas Breast |
G | BRCA2 | D | Suprarenal, CNS, lung | SD |
| 9 | F | 47 | FS (12) | ADC | N | U |
BRCA1 BRCA2 BRCA2 |
VUS | Bone, lymph nodes, muscle | SD |
| 10 | F | 52 | CS (25) | ADC | N | S | BRCA1 | VUS | Suprarenal, lung, lymph nodes | SD |
| 11 | M | 68 | CS (60) | ADC | Y Prostate |
G | BRCA1 | VUS | Pleural | SD |
| 12 | F | 73 | FS (7) | LCC | N | G | BRCA1 | VUS | Bone | PD |
| 13 | F | 67 | NS | SCC | UK | G | BRCA2 | VUS | NR | PR |
| 14 | M | 68 | CS (53) | ADC | N | G | BRCA2 | VUS | Lung | PD |
| 15 | F | 61 | FS (17) | ADC | Y Breast |
G | BRCA2 | VUS | Lung | SD |
| 16 | M | 61 | CS (45) | LCC | N | S | BRCA2 | VUS | Pleural effusion | SD |
| 17 | M | 56 | CS (40) | ADC | Y Prostate |
S | BRCA2 | VUS | Lung | SD |
| 18 | F | 71 | CS (42) | LCC | N | G | BRCA2 | VUS | Suprarenal, CNS, lymph nodes | PD |
| 19 | M | 62 | CS (43) | SCC | N | S | BRCA2 | VUS | Bone, lung, lymph nodes, pleural | PD |
| 20 | M | 63 | CS (50) | ADC | Y MPM |
S | BRCA2 | VUS | Adrenal, Bone, liver, lymph nodes | SD |
ADC, adenocarcinoma; CS, current smoker; D, deleterious; FS, former smoker; G, germline; LCC, large cell carcinoma; M/F, male/female; MPM, malignant pleural mesothelioma; NS, never smoker; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors, RR, response rate; S somatic; SCC, squamous cell carcinoma; SD, stable disease; U, undetermined; UK, unknown; VUS, variants of unknown significance; Y/N: yes/no.
a
Best RR to chemotherapy is according to the RECIST 1.1 criteria by the investigator. BRCA origin: S, G, U, MPM.